Stockreport

Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress

Immunocore Holdings plc - American Depositary Shares  (IMCR) 
PDF Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress Data from Phase 1 dose escalation trial [Read more]